open–labeled, multicenter phase II study of the evaluation of single administration Pegfilgrastim once per cycle as an adjunct to R-FC (rituximab plus fludarabine and cyclophosphamide) or FC combination chemotherapy in patients with newly diagnosed or relapsed chronic lymphocytic leukemia
Latest Information Update: 18 Sep 2019
At a glance
- Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Neutropenia
- Focus Therapeutic Use
- Acronyms M2peg-CLL
- 19 Oct 2016 New trial record